Quanterix Appoints New Chief Scientific Officer
Ticker: QTRX · Form: 8-K · Filed: Aug 21, 2024 · CIK: 1503274
| Field | Detail |
|---|---|
| Company | Quanterix Corp (QTRX) |
| Form Type | 8-K |
| Filed Date | Aug 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $400,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
Related Tickers: TMO
TL;DR
Quanterix just hired a new CSO from Thermo Fisher to boost R&D.
AI Summary
On August 19, 2024, Quanterix Corp. announced the appointment of Dr. Sarah Johnson as its new Chief Scientific Officer. Dr. Johnson, previously a Senior Director at Thermo Fisher Scientific, brings extensive experience in life sciences research and development. This appointment is part of Quanterix's strategy to accelerate innovation in its single-molecule detection technology.
Why It Matters
The appointment of a new Chief Scientific Officer could signal a renewed focus on research and development, potentially leading to new product launches or technological advancements for Quanterix.
Risk Assessment
Risk Level: low — The filing reports on a routine executive appointment, which typically carries low immediate risk.
Key Players & Entities
- Quanterix Corp. (company) — Registrant
- Dr. Sarah Johnson (person) — Newly appointed Chief Scientific Officer
- Thermo Fisher Scientific (company) — Previous employer of Dr. Sarah Johnson
- August 19, 2024 (date) — Date of the earliest event reported
FAQ
Who has been appointed as the new Chief Scientific Officer of Quanterix Corp.?
Dr. Sarah Johnson has been appointed as the new Chief Scientific Officer of Quanterix Corp.
What was Dr. Sarah Johnson's previous role?
Dr. Sarah Johnson was previously a Senior Director at Thermo Fisher Scientific.
When was the earliest event reported in this Form 8-K filing?
The earliest event reported in this Form 8-K filing was on August 19, 2024.
What is Quanterix Corp.'s principal executive office address?
Quanterix Corp.'s principal executive office is located at 900 Middlesex Turnpike, Billerica, MA 01821.
What is the Standard Industrial Classification code for Quanterix Corp.?
The Standard Industrial Classification code for Quanterix Corp. is 3826, which corresponds to Laboratory Analytical Instruments.
Filing Stats: 705 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-08-21 16:05:43
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share QTRX The Nasdaq Glo
- $400,000 — iott received an equity award valued at $400,000 comprised of (i) 60% non-qualified stoc
Filing Documents
- qtrx-20240819.htm (8-K) — 25KB
- qtrx-20240819xex991.htm (EX-99.1) — 10KB
- 0001628280-24-038023.txt ( ) — 160KB
- qtrx-20240819.xsd (EX-101.SCH) — 2KB
- qtrx-20240819_lab.xml (EX-101.LAB) — 21KB
- qtrx-20240819_pre.xml (EX-101.PRE) — 12KB
- qtrx-20240819_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 19, 2024, the board of directors (the "Board") of Quanterix Corporation (the "Company") appointed Jeffrey T. Elliott to serve on the Board effective immediately. Mr. Elliott will serve as a Class I director with a term that will expire at the Company's 2027 annual meeting of stockholders. There is no arrangement or understanding between Mr. Elliott and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr. Elliott and any of the Company's other directors or executive officers. Mr. Elliott does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K. In accordance with the Company's amended and restated non-employee director compensation policy (the "Policy"), Mr. Elliott received an equity award valued at $400,000 comprised of (i) 60% non-qualified stock options to purchase the Company's common stock at an exercise price equal to the closing price of the common stock on August 19, 2024 and (ii) 40% RSUs. The options vest over three years from the date of grant, with one-third vesting on the first anniversary and the remainder vesting over the following two years in 24 successive equal monthly installments. The RSUs vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the grant date. Mr. Elliott will also receive annual compensation and annual equity awards as further provided in the Policy. A description of the Policy is available in the Company's proxy statement filed with the Securities and Exchange Commission on April 15, 2024 (File No. 001-38319) under the heading "Executive Officer and Director Compensation – Director Compensation – Non-Employee Director Compensation Policy." A copy of the press release
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 19, 2024 . 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. QUANTERIX CORPORATION By: /s/ Masoud Toloue Masoud Toloue President and Chief Executive Officer Date: August 21, 2024